Clinical Trial Update: A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study of birabresib (MK-8628), a BET inhibitor, completed with results posted in 2018 for selected advanced solid tumors including NUT midl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castrate-resistant Prostate Cancer
• Non-small Cell Lung Cancer with Rearranged Alk Gene Fusion Protein or Kras Mutation
• Nut Midline Carcinoma
• Pancreatic Ductal Adenocarcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• birabresib (birabresib)

Snippet

Sponsor: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: NUT Midline Carcinoma, Triple Negative Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2018-10-01